Semiconductors
Compare Stocks
5 / 10Stock Comparison
AEHR vs NVDA vs KLAC vs LRCX vs AMD
Revenue, margins, valuation, and 5-year total return — side by side.
Semiconductors
Semiconductors
Semiconductors
Semiconductors
AEHR vs NVDA vs KLAC vs LRCX vs AMD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Semiconductors | Semiconductors | Semiconductors | Semiconductors | Semiconductors |
| Market Cap | $2.79B | $5.14T | $231.68B | $357.66B | $665.93B |
| Revenue (TTM) | $49M | $215.94B | $13.10B | $21.68B | $37.45B |
| Net Income (TTM) | $-11M | $120.07B | $4.67B | $6.71B | $4.99B |
| Gross Margin | 30.2% | 71.1% | 61.8% | 50.0% | 50.3% |
| Operating Margin | -27.8% | 60.4% | 42.1% | 34.3% | 11.7% |
| Forward P/E | — | 25.6x | 47.9x | 50.7x | 59.7x |
| Total Debt | $11M | $11.41B | $6.09B | $4.76B | $4.47B |
| Cash & Equiv. | $25M | $10.61B | $2.08B | $6.39B | $5.54B |
AEHR vs NVDA vs KLAC vs LRCX vs AMD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Aehr Test Systems (AEHR) | 100 | 5530.9 | +5430.9% |
| NVIDIA Corporation (NVDA) | 100 | 2381.7 | +2281.7% |
| KLA Corporation (KLAC) | 100 | 1002.1 | +902.1% |
| Lam Research Corpor… (LRCX) | 100 | 1046.4 | +946.4% |
| Advanced Micro Devi… (AMD) | 100 | 759.2 | +659.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AEHR vs NVDA vs KLAC vs LRCX vs AMD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
AEHR is the #2 pick in this set and the best alternative if momentum is your priority.
- +9.9% vs NVDA's +80.7%
NVDA carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 65.5%, EPS growth 66.7%, 3Y rev CAGR 100.0%
- 239.0% 10Y total return vs AEHR's 70.3%
- Lower volatility, beta 1.73, Low D/E 7.3%, current ratio 3.91x
- PEG 0.27 vs AMD's 11.55
KLAC ranks third and is worth considering specifically for income & stability and defensive.
- Dividend streak 8 yrs, beta 2.20, yield 0.4%
- Beta 2.20, yield 0.4%, current ratio 2.62x
- 0.4% yield, 8-year raise streak, vs LRCX's 0.3%, (2 stocks pay no dividend)
LRCX lags the leaders in this set but could rank higher in a more targeted comparison.
Among these 5 stocks, AMD doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 65.5% revenue growth vs AEHR's -20.2% | |
| Value | Lower P/E (25.6x vs 59.7x), PEG 0.27 vs 11.55 | |
| Quality / Margins | 55.6% margin vs AEHR's -22.7% | |
| Stability / Safety | Beta 1.73 vs AEHR's 4.77, lower leverage | |
| Dividends | 0.4% yield, 8-year raise streak, vs LRCX's 0.3%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +9.9% vs NVDA's +80.7% | |
| Efficiency (ROA) | 58.1% ROA vs AEHR's -7.5%, ROIC 81.8% vs -3.0% |
AEHR vs NVDA vs KLAC vs LRCX vs AMD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
AEHR vs NVDA vs KLAC vs LRCX vs AMD — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
NVDA leads in 4 of 6 categories
AEHR leads 0 • KLAC leads 0 • LRCX leads 0 • AMD leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
NVDA leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NVDA is the larger business by revenue, generating $215.9B annually — 4404.1x AEHR's $49M. NVDA is the more profitable business, keeping 55.6% of every revenue dollar as net income compared to AEHR's -22.7%. On growth, NVDA holds the edge at +73.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $49M | $215.9B | $13.1B | $21.7B | $37.5B |
| EBITDAEarnings before interest/tax | -$10M | $133.2B | $5.9B | $7.8B | $6.6B |
| Net IncomeAfter-tax profit | -$11M | $120.1B | $4.7B | $6.7B | $5.0B |
| Free Cash FlowCash after capex | -$14M | $96.7B | $4.0B | $6.5B | $8.6B |
| Gross MarginGross profit ÷ Revenue | +30.2% | +71.1% | +61.8% | +50.0% | +50.3% |
| Operating MarginEBIT ÷ Revenue | -27.8% | +60.4% | +42.1% | +34.3% | +11.7% |
| Net MarginNet income ÷ Revenue | -22.7% | +55.6% | +35.7% | +30.9% | +13.3% |
| FCF MarginFCF ÷ Revenue | -28.1% | +44.8% | +30.7% | +29.8% | +22.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -26.5% | +73.2% | +11.5% | +23.8% | +37.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.2% | +97.8% | +11.8% | +40.8% | +90.9% |
Valuation Metrics
NVDA leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 43.2x trailing earnings, NVDA trades at a 72% valuation discount to AMD's 154.1x P/E. Adjusting for growth (PEG ratio), NVDA offers better value at 0.45x vs AMD's 29.84x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $2.8B | $5.14T | $231.7B | $357.7B | $665.9B |
| Enterprise ValueMkt cap + debt − cash | $2.8B | $5.14T | $235.7B | $356.0B | $664.9B |
| Trailing P/EPrice ÷ TTM EPS | -702.00x | 43.16x | 58.06x | 69.01x | 154.14x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 25.55x | 47.92x | 50.65x | 59.65x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.45x | 1.84x | 3.08x | 29.84x |
| EV / EBITDAEnterprise value multiple | — | 38.59x | 41.82x | 56.63x | 99.26x |
| Price / SalesMarket cap ÷ Revenue | 47.39x | 23.80x | 19.06x | 19.40x | 19.22x |
| Price / BookPrice ÷ Book value/share | 21.97x | 32.85x | 50.26x | 37.47x | 10.61x |
| Price / FCFMarket cap ÷ FCF | — | 53.17x | 61.92x | 66.06x | 98.88x |
Profitability & Efficiency
NVDA leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
KLAC delivers a 89.1% return on equity — every $100 of shareholder capital generates $89 in annual profit, vs $-8 for AEHR. AMD carries lower financial leverage with a 0.07x debt-to-equity ratio, signaling a more conservative balance sheet compared to KLAC's 1.30x. On the Piotroski fundamental quality scale (0–9), KLAC scores 9/9 vs AEHR's 1/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -8.5% | +76.3% | +89.1% | +65.8% | +8.1% |
| ROA (TTM)Return on assets | -7.5% | +58.1% | +28.3% | +31.4% | +6.5% |
| ROICReturn on invested capital | -3.0% | +81.8% | +46.5% | +55.7% | +4.7% |
| ROCEReturn on capital employed | -3.2% | +97.2% | +46.1% | +40.4% | +5.7% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 | 9 | 8 | 8 |
| Debt / EquityFinancial leverage | 0.09x | 0.07x | 1.30x | 0.48x | 0.07x |
| Net DebtTotal debt minus cash | -$14M | $807M | $4.0B | -$1.6B | -$1.1B |
| Cash & Equiv.Liquid assets | $25M | $10.6B | $2.1B | $6.4B | $5.5B |
| Total DebtShort + long-term debt | $11M | $11.4B | $6.1B | $4.8B | $4.5B |
| Interest CoverageEBIT ÷ Interest expense | — | 545.03x | 19.38x | 58.92x | 33.19x |
Total Returns (Dividends Reinvested)
Evenly matched — AEHR and NVDA each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AEHR five years ago would be worth $398,515 today (with dividends reinvested), compared to $46,048 for LRCX. Over the past 12 months, AEHR leads with a +991.6% total return vs NVDA's +80.7%. The 3-year compound annual growth rate (CAGR) favors NVDA at 93.6% vs AEHR's 50.7% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +311.8% | +12.0% | +38.5% | +54.9% | +82.8% |
| 1-Year ReturnPast 12 months | +991.6% | +80.7% | +155.0% | +282.9% | +307.0% |
| 3-Year ReturnCumulative with dividends | +242.3% | +625.9% | +364.8% | +448.8% | +329.8% |
| 5-Year ReturnCumulative with dividends | +3885.1% | +1328.9% | +460.4% | +360.5% | +418.3% |
| 10-Year ReturnCumulative with dividends | +7029.7% | +23902.3% | +2511.9% | +3815.1% | +11090.7% |
| CAGR (3Y)Annualised 3-year return | +50.7% | +93.6% | +66.9% | +76.4% | +62.6% |
Risk & Volatility
NVDA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
NVDA is the less volatile stock with a 1.73 beta — it tends to amplify market swings less than AEHR's 4.77 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVDA currently trades 97.6% from its 52-week high vs AEHR's 89.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 4.77x | 1.73x | 2.20x | 2.54x | 2.30x |
| 52-Week HighHighest price in past year | $102.48 | $216.80 | $1939.36 | $298.00 | $430.57 |
| 52-Week LowLowest price in past year | $8.06 | $112.28 | $675.27 | $72.91 | $96.88 |
| % of 52W HighCurrent price vs 52-week peak | +89.1% | +97.6% | +90.9% | +96.1% | +94.9% |
| RSI (14)Momentum oscillator 0–100 | 67.6 | 60.7 | 59.1 | 69.9 | 81.2 |
| Avg Volume (50D)Average daily shares traded | 3.0M | 164.5M | 971K | 9.7M | 36.4M |
Analyst Outlook
Evenly matched — KLAC and LRCX each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: AEHR as "Hold", NVDA as "Buy", KLAC as "Buy", LRCX as "Buy", AMD as "Buy". Consensus price targets imply 31.8% upside for NVDA (target: $279) vs -32.1% for AEHR (target: $62). For income investors, KLAC offers the higher dividend yield at 0.38% vs LRCX's 0.31%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $62.00 | $278.83 | $1819.38 | $290.65 | $310.86 |
| # AnalystsCovering analysts | 3 | 79 | 44 | 50 | 70 |
| Dividend YieldAnnual dividend ÷ price | — | +0.0% | +0.4% | +0.3% | — |
| Dividend StreakConsecutive years of raises | — | 2 | 8 | 11 | 0 |
| Dividend / ShareAnnual DPS | — | $0.04 | $6.76 | $0.89 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | +0.8% | +0.9% | +1.0% | +0.2% |
NVDA leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 2 categories are tied.
AEHR vs NVDA vs KLAC vs LRCX vs AMD: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is AEHR or NVDA or KLAC or LRCX or AMD a better buy right now?
For growth investors, NVIDIA Corporation (NVDA) is the stronger pick with 65.
5% revenue growth year-over-year, versus 23. 7% for Lam Research Corporation (LRCX). NVIDIA Corporation (NVDA) offers the better valuation at 43. 2x trailing P/E (25. 6x forward), making it the more compelling value choice. Analysts rate NVIDIA Corporation (NVDA) a "Buy" — based on 79 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — AEHR or NVDA or KLAC or LRCX or AMD?
On trailing P/E, NVIDIA Corporation (NVDA) is the cheapest at 43.
2x versus Advanced Micro Devices, Inc. at 154. 1x. On forward P/E, NVIDIA Corporation is actually cheaper at 25. 6x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: NVIDIA Corporation wins at 0. 27x versus Advanced Micro Devices, Inc. 's 11. 55x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — AEHR or NVDA or KLAC or LRCX or AMD?
Over the past 5 years, Aehr Test Systems (AEHR) delivered a total return of +38.
9%, compared to +360. 5% for Lam Research Corporation (LRCX). Over 10 years, the gap is even starker: NVDA returned +239. 0% versus KLAC's +25. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — AEHR or NVDA or KLAC or LRCX or AMD?
By beta (market sensitivity over 5 years), NVIDIA Corporation (NVDA) is the lower-risk stock at 1.
73β versus Aehr Test Systems's 4. 77β — meaning AEHR is approximately 177% more volatile than NVDA relative to the S&P 500. On balance sheet safety, Advanced Micro Devices, Inc. (AMD) carries a lower debt/equity ratio of 7% versus 130% for KLA Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — AEHR or NVDA or KLAC or LRCX or AMD?
By revenue growth (latest reported year), NVIDIA Corporation (NVDA) is pulling ahead at 65.
5% versus 23. 7% for Lam Research Corporation (LRCX). On earnings-per-share growth, the picture is similar: Advanced Micro Devices, Inc. grew EPS 165. 0% year-over-year, compared to 0. 0% for Aehr Test Systems. Over a 3-year CAGR, NVDA leads at 100. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — AEHR or NVDA or KLAC or LRCX or AMD?
NVIDIA Corporation (NVDA) is the more profitable company, earning 55.
6% net margin versus -6. 6% for Aehr Test Systems — meaning it keeps 55. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVDA leads at 60. 4% versus -7. 3% for AEHR. At the gross margin level — before operating expenses — NVDA leads at 71. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is AEHR or NVDA or KLAC or LRCX or AMD more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, NVIDIA Corporation (NVDA) is the more undervalued stock at a PEG of 0. 27x versus Advanced Micro Devices, Inc. 's 11. 55x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, NVIDIA Corporation (NVDA) trades at 25. 6x forward P/E versus 59. 7x for Advanced Micro Devices, Inc. — 34. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVDA: 31. 8% to $278. 83.
08Which pays a better dividend — AEHR or NVDA or KLAC or LRCX or AMD?
In this comparison, KLAC (0.
4% yield), LRCX (0. 3% yield) pay a dividend. AEHR, NVDA, AMD do not pay a meaningful dividend and should not be held primarily for income.
09Is AEHR or NVDA or KLAC or LRCX or AMD better for a retirement portfolio?
For long-horizon retirement investors, NVIDIA Corporation (NVDA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+239.
0% 10Y return). KLA Corporation (KLAC) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NVDA: +239. 0%, KLAC: +25. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between AEHR and NVDA and KLAC and LRCX and AMD?
Both stocks operate in the Technology sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: AEHR is a small-cap quality compounder stock; NVDA is a mega-cap high-growth stock; KLAC is a large-cap high-growth stock; LRCX is a large-cap high-growth stock; AMD is a large-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.